Tenon Medical Inc. (TNON) has regained compliance with Nasdaq’s minimum bid price requirement after completing a 1-for-35 reverse stock split, the company said on Aug. 24.
The Los Gatos, California-based medical device maker received a deficiency notice from Nasdaq on Feb. 25, 2026, after its shares traded below $1.00 for 30 consecutive business days. The reverse stock split, effective Aug. 10, 2026, adjusted the share price upward while reducing the total share count. Over the subsequent 10 trading days, Tenon Medical’s stock maintained a closing bid price of at least $1.00 per share, satisfying Nasdaq’s Listing Rule 5550(a)(2).
Nasdaq’s Listing Qualifications staff confirmed in writing that the compliance issue is resolved, allowing TNON to continue trading on the Nasdaq Capital Market. The company develops medical devices for sacro-pelvic disorders, including two systems for sacroiliac joint treatment.
Tenon Medical was incorporated in Delaware in 2012 and is headquartered in Los Gatos, California.
